Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
2022
Haiyang Guo | Jun Zhang | Chao Qin | Hang Yan | Tao Liu | Haiyang Hu | Shengjie Tang | Shoujun Tang | Haining Zhou
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies have significantly improved the prognosis of NSCLC. However, the vast majority of advanced NSCLC develop resistance to current therapies and eventually progress. In this review, we discuss current and potential therapies for NSCLC, focusing on targeted therapies and immunotherapies. We highlight the future role of metabolic therapies and combination therapies in NSCLC.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
